Fortunately, emerging agents targeting HIF-2α are promising anti-tumor therapeutics, providing alternative candidates for hypoxia-targeted drugs when all HIFs beyond HIF-1α are taken into consideration. This evidence concerns the gene EPAS1 and neoplasm.